Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$3.17 - $8.05 $221,900 - $563,500
70,000 Added 233.33%
100,000 $424,000
Q1 2024

May 15, 2024

BUY
$4.07 - $8.68 $122,100 - $260,400
30,000 New
30,000 $217,000
Q2 2023

Aug 14, 2023

BUY
$2.76 - $5.27 $126,959 - $242,419
46,000 New
46,000 $185,000

Others Institutions Holding ABEO

About ABEONA THERAPEUTICS INC.


  • Ticker ABEO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 5,950,380
  • Market Cap $33.9M
  • Description
  • Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-a...
More about ABEO
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.